This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Breast Cancer Liquid Biopsy industry.
What is the anticipated market size of the breast cancer liquid biopsy industry over the next few years?
The breast cancer liquid biopsy market size has grown rapidly in recent years. It will grow from $0.78 billion in 2024 to $0.90 billion in 2025 at a compound annual growth rate (CAGR) of 15.0%. The growth in the historic period can be attributed to advancements in next-generation sequencing (ngs), increasing prevalence of breast cancer, growing demand for non-invasive diagnostic methods, rising adoption of personalized medicine, and increased funding for cancer research.
The breast cancer liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $1.56 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to technological advancements in liquid biopsy assays, increasing adoption of liquid biopsy in early cancer screening, rising demand for real-time cancer monitoring, expanding applications in precision oncology, growing investments in liquid biopsy research and development. Major trends in the forecast period include integration of artificial intelligence in liquid biopsy analysis, advancements in single-cell sequencing, development of multi-omics liquid biopsy platforms, improvement in liquid biopsy sensitivity and specificity, and adoption of digital pcr for ultra-precise mutation detection.
Download Your Free Sample PDF:
What emerging drivers are expected to shape the future of the breast cancer liquid biopsy market?
The increase in breast cancer cases is expected to propel the growth of the breast cancer liquid biopsy market going forward. Breast cancer is a type of cancer that develops in the cells of the breast, typically in the lobules (milk-producing glands) or ducts (pathways that carry milk to the nipple). Breast cancer cases are on the rise due to factors including genetic predisposition, hormonal imbalances, aging population, lifestyle changes, obesity, alcohol consumption, lack of physical activity, exposure to radiation, and environmental pollutants. A breast cancer liquid biopsy is used in treatment to detect circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, helping to monitor the disease in real-time. It aids in assessing treatment response, detecting therapy resistance, and identifying genetic mutations for targeted therapies. For instance, in 2025, according to the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, the number of new breast cancer cases is expected to rise to 319,750 in 2025, up from 313,510 cases in 2024. Therefore, the increase in breast cancer cases is driving the growth of the breast cancer liquid biopsy market.
What emerging segments are shaping the future landscape of the breast cancer liquid biopsy industry?
The breast cancer liquid biopsy market covered in this report is segmented –
1) By Product: Consumables, Kits
2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers
3) By Application: Early Detection Or Screening, Diagnosis, Other Applications
4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories
Subsegments:
1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes
2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits
View The Full Market Report:
What are the top market trends driving innovation in the breast cancer liquid biopsy industry?
Major companies operating in the breast cancer liquid biopsy market are focusing on developing innovative products, such as companion diagnostics, to enable personalized treatment approaches by identifying patients who benefit from specific therapies. Companion diagnostics utilize liquid biopsy technologies to detect biomarkers such as genetic mutations, circulating tumor DNA (ctDNA), or protein expressions indicative of treatment responsiveness. For instance, in January 2023, Guardant Health Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant), a treatment for advanced or metastatic breast cancer patients with ESR1 mutations. This approval enables oncologists to use the test for comprehensive genomic profiling, identifying patients who may benefit from the targeted therapy. It marks Guardant Health’s first U.S. Food and Drug Administration (FDA) approval in breast cancer and expands its role in precision oncology.
How are key players in the breast cancer liquid biopsy market strengthening their market position?
Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc
Which geographic areas are contributing significantly to the growth of the breast cancer liquid biopsy sector?
North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Breast Cancer Liquid Biopsy Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Breast Cancer Liquid Biopsy Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment